Clinical Trial Update: Extension Study to Evaluate the Safety and Efficacy of PT003, PT001, and PT005 in Subjects With Moderate to Very Severe COPD, With Spiriva® Handihaler® (PINNACLE 3) [Phase 3]

View source ↗

Summary

This is a completed Phase 3 PINNACLE 3 extension study evaluating PT003, PT001, and PT005 in moderate to very severe COPD, with results posted in 2017 to assess…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Chronic Obstructive Pulmonary Disease

Drugs mentioned

• PT001
• PT003
• PT005

Snippet

Sponsor: Pearl Therapeutics, Inc. | Conditions: Chronic Obstructive Pulmonary Disease (COPD) | Phase 3 | Status: COMPLETED | Results posted: 2017-02-06